
Creating breakthroughs in mental health
ATAI invests in and develops multiple mental health compounds including ketamine derivatives and ibogaine analogs. While broader in scope than Gilgamesh, ATAI previously acquired Gilgamesh founders' earlier companies, creating direct lineage overlap in psychedelic and ibogaine chemistry.
Free